Opko Health - Der nächste Blockbuster (Seite 274)
eröffnet am 10.12.13 19:42:20 von
neuester Beitrag 07.05.24 22:55:13 von
neuester Beitrag 07.05.24 22:55:13 von
Beiträge: 3.051
ID: 1.189.336
ID: 1.189.336
Aufrufe heute: 5
Gesamt: 261.286
Gesamt: 261.286
Aktive User: 0
ISIN: US68375N1037 · WKN: A0MUUJ · Symbol: XCY
1,2500
USD
-3,85 %
-0,0500 USD
Letzter Kurs 02:00:00 Nasdaq
Neuigkeiten
07.05.24 · globenewswire  |
03.05.24 · globenewswire |
05.03.24 · globenewswire |
27.02.24 · globenewswire |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,8450 | +146,00 | |
| 0,5700 | +55,23 | |
| 0,7200 | +47,03 | |
| 5,4500 | +41,56 | |
| 1,0000 | +33,33 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 13,800 | -13,86 | |
| 4,1900 | -14,49 | |
| 0,9235 | -16,88 | |
| 5,2500 | -19,23 | |
| 2,5600 | -70,32 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 63.169.467 von Wallstreeter2020 am 29.03.20 19:20:05
Danke, werde mir in aller Ruhe anschauen. Das Thema interessiert mich eigentlich mehr als vorübergehende Themen. Womit langfristig Geld verdient werden kann, ist für den Aktienkurs auf Dauer relevant.
Zitat von Wallstreeter2020: Das Unternehmen stellte gestern den Halbjahresbericht der Studie von Somatrogon vor.
https://www.opkobiologics.com/pipeline/product-candidates/hg…
Danke, werde mir in aller Ruhe anschauen. Das Thema interessiert mich eigentlich mehr als vorübergehende Themen. Womit langfristig Geld verdient werden kann, ist für den Aktienkurs auf Dauer relevant.
Zwischenbericht Somatrogon
Wann wird für gewöhnlich von Opko ein Zwischenberichte veröffentlicht ?Das Unternehmen stellte gestern den Halbjahresbericht der Studie von Somatrogon vor.
https://www.opkobiologics.com/pipeline/product-candidates/hg…
Grüße an alle
Antwort auf Beitrag Nr.: 63.167.454 von Hastdunicht am 29.03.20 14:34:03
Oder C. Er hat einfach sein Geld während der Krise hier angelegt.
B braucht er nicht, denn der Boden bildet sich von alleine irgendwo im Bereich 1,20 - 1,40€. Von diesem Boden aus gehen die Sprünge nach oben.
A ist höchstwahrscheinlich als Komponente dabei, denn er will ja Gewinne machen. Und sicherlich weiss ein CEO mehr als wir.
An seinen Transaktionen kann man seine Einkaufskurse erkennen: zwischen 1,42 - 1.63 (USD, nicht EUR) hat er eingekauft, höher nicht. Da hat er im Grunde genommen nichts falsch gemacht. In der Nähe des Bodens gekauft und das Geld ist in stürmischen Zeiten angelegt. Bei einem passenden Sprung nach oben kann er dann irgendwann verkaufen.
Zitat von Hastdunicht: Moin. Ich denke da gibt es zwei Möglichkeiten
A. Er weiß mehr und es geht bald Richtung Norden.
B. Er kauft auf um den Kurs stabil zu halten.
Ich hoffe und tippe aber auf a.
Oder C. Er hat einfach sein Geld während der Krise hier angelegt.
B braucht er nicht, denn der Boden bildet sich von alleine irgendwo im Bereich 1,20 - 1,40€. Von diesem Boden aus gehen die Sprünge nach oben.
A ist höchstwahrscheinlich als Komponente dabei, denn er will ja Gewinne machen. Und sicherlich weiss ein CEO mehr als wir.
An seinen Transaktionen kann man seine Einkaufskurse erkennen: zwischen 1,42 - 1.63 (USD, nicht EUR) hat er eingekauft, höher nicht. Da hat er im Grunde genommen nichts falsch gemacht. In der Nähe des Bodens gekauft und das Geld ist in stürmischen Zeiten angelegt. Bei einem passenden Sprung nach oben kann er dann irgendwann verkaufen.
Das Bild unten (dieses Quartal noch nicht zu sehen) zeigt, dass alles gebunkert wird. Keine Aktie verkauft.
Antwort auf Beitrag Nr.: 63.166.866 von Malecon am 29.03.20 13:22:07Moin. Ich denke da gibt es zwei Möglichkeiten
A. Er weiß mehr und es geht bald Richtung Norden.
B. Er kauft auf um den Kurs stabil zu halten.
Ich hoffe und tippe aber auf a.
A. Er weiß mehr und es geht bald Richtung Norden.
B. Er kauft auf um den Kurs stabil zu halten.
Ich hoffe und tippe aber auf a.
Trading Spotlight
Phillip Md Et Al Frost Acquires 200,000 Shares of Opko Health Inc.
CEO Phillip Md Et Al Frost purchased 200,000 shares of Opko Health stock in a transaction dated Thursday, March 26th. The shares were purchased at an average cost of $1.38 per share, for a total transaction of $276,000.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $4,235,152.38.
https://redmondregister.com/2020/03/29/phillip-md-et-al-fros…
Und wieder hat er an einem Donnerstag zugeschlagen.
Das war schon die letzte Woche und früher oft so. Warum liebt er Kurse donnerstags? Und warum deckt er sich seit Januar fast jede Woche ein?
Phillip Md Et Al Frost also recently made the following trade(s):
• On Thursday, March 19th, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The shares were purchased at an average cost of $1.44 per share, for a total transaction of $144,000.00.
• On Tuesday, March 10th, Phillip Md Et Al Frost purchased 300,000 shares of Opko Health stock. The shares were purchased at an average cost of $1.61 per share, for a total transaction of $483,000.00.
• On Monday, March 2nd, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The shares were purchased at an average cost of $1.49 per share, for a total transaction of $149,000.00.
• On Thursday, February 27th, Phillip Md Et Al Frost acquired 250,000 shares of Opko Health stock. The stock was bought at an average cost of $1.44 per share, for a total transaction of $360,000.00.
• On Thursday, February 13th, Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock. The stock was bought at an average cost of $1.57 per share, for a total transaction of $157,000.00.
• On Tuesday, February 11th, Phillip Md Et Al Frost acquired 14,239 shares of Opko Health stock. The stock was bought at an average cost of $1.59 per share, for a total transaction of $22,640.01.
• On Thursday, February 6th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The stock was bought at an average cost of $1.58 per share, for a total transaction of $79,000.00.
• On Thursday, January 30th, Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock. The stock was bought at an average cost of $1.42 per share, for a total transaction of $142,000.00.
• On Thursday, January 23rd, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The stock was bought at an average cost of $1.63 per share, for a total transaction of $81,500.00.
• On Friday, January 17th, Phillip Md Et Al Frost acquired 22,262 shares of Opko Health stock. The stock was bought at an average cost of $1.56 per share, for a total transaction of $34,728.72.
https://redmondregister.com/2020/03/29/phillip-md-et-al-fros…
CEO Phillip Md Et Al Frost purchased 200,000 shares of Opko Health stock in a transaction dated Thursday, March 26th. The shares were purchased at an average cost of $1.38 per share, for a total transaction of $276,000.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares of the company’s stock, valued at $4,235,152.38.
https://redmondregister.com/2020/03/29/phillip-md-et-al-fros…
Und wieder hat er an einem Donnerstag zugeschlagen.
Das war schon die letzte Woche und früher oft so. Warum liebt er Kurse donnerstags? Und warum deckt er sich seit Januar fast jede Woche ein?Phillip Md Et Al Frost also recently made the following trade(s):
• On Thursday, March 19th, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The shares were purchased at an average cost of $1.44 per share, for a total transaction of $144,000.00.
• On Tuesday, March 10th, Phillip Md Et Al Frost purchased 300,000 shares of Opko Health stock. The shares were purchased at an average cost of $1.61 per share, for a total transaction of $483,000.00.
• On Monday, March 2nd, Phillip Md Et Al Frost purchased 100,000 shares of Opko Health stock. The shares were purchased at an average cost of $1.49 per share, for a total transaction of $149,000.00.
• On Thursday, February 27th, Phillip Md Et Al Frost acquired 250,000 shares of Opko Health stock. The stock was bought at an average cost of $1.44 per share, for a total transaction of $360,000.00.
• On Thursday, February 13th, Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock. The stock was bought at an average cost of $1.57 per share, for a total transaction of $157,000.00.
• On Tuesday, February 11th, Phillip Md Et Al Frost acquired 14,239 shares of Opko Health stock. The stock was bought at an average cost of $1.59 per share, for a total transaction of $22,640.01.
• On Thursday, February 6th, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The stock was bought at an average cost of $1.58 per share, for a total transaction of $79,000.00.
• On Thursday, January 30th, Phillip Md Et Al Frost acquired 100,000 shares of Opko Health stock. The stock was bought at an average cost of $1.42 per share, for a total transaction of $142,000.00.
• On Thursday, January 23rd, Phillip Md Et Al Frost acquired 50,000 shares of Opko Health stock. The stock was bought at an average cost of $1.63 per share, for a total transaction of $81,500.00.
• On Friday, January 17th, Phillip Md Et Al Frost acquired 22,262 shares of Opko Health stock. The stock was bought at an average cost of $1.56 per share, for a total transaction of $34,728.72.
https://redmondregister.com/2020/03/29/phillip-md-et-al-fros…
OPKO Health Reports Interim Results for Two Ongoing RAYALDEE Studies
• Phase 4 Head-to-Head Study in Patients with Stage 3 or 4 CKD.
• Phase 2 Trial in Patients with Stage 5 CKD on Dialysis.
https://www.biospace.com/article/releases/opko-health-report…
• Phase 4 Head-to-Head Study in Patients with Stage 3 or 4 CKD.
• Phase 2 Trial in Patients with Stage 5 CKD on Dialysis.
https://www.biospace.com/article/releases/opko-health-report…
Meinte hier nicht irgendjemand, das am Samstag News kommen welche nichts mit Corona zu tun haben? Die arbeiten doch noch an Medikamenten oder
OPKO Health's BioReference Laboratories and City of Miami Provide Testing for Coronavirus Disease 2019 (COVID-19)
BioReference will offer COVID-19 testing for public drive-through facilities for Miami residents and Larkin Community Hospital
ELMWOOD PARK, N.J., March 24, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a collaboration with the City of Miami to provide coronavirus disease 2019 (COVID-19) testing. BioReference will provide COVID-19 testing at drive-through locations for Miami residents by appointment.
BioReference is also announcing that they are providing testing for drive-through testing centers in South Florida, Hialeah and Hollywood through a collaboration with Larkin Community Hospital.
"We all are responsible for helping to control the spread of this virus," said Francis Suarez, Mayor of the City of Miami. "As an individual who tested positive for COVID-19, I have a duty to the City of Miami to bring my city's residents access to testing and information, and through our partnership with BioReference, we can help address this public health crisis."
"BioReference continues to prioritize expanding public access to COVID-19 testing across the nation," said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. "The importance of high-quality, reliable, scalable laboratory tests available is a critical part of the response in the effort to contain COVID-19."
https://www.opko.com/investors/news-events/press-releases/de…
BioReference will offer COVID-19 testing for public drive-through facilities for Miami residents and Larkin Community Hospital
ELMWOOD PARK, N.J., March 24, 2020 /PRNewswire/ -- BioReference Laboratories, Inc., an OPKO Health company (NASDAQ: OPK), today announced a collaboration with the City of Miami to provide coronavirus disease 2019 (COVID-19) testing. BioReference will provide COVID-19 testing at drive-through locations for Miami residents by appointment.
BioReference is also announcing that they are providing testing for drive-through testing centers in South Florida, Hialeah and Hollywood through a collaboration with Larkin Community Hospital.
"We all are responsible for helping to control the spread of this virus," said Francis Suarez, Mayor of the City of Miami. "As an individual who tested positive for COVID-19, I have a duty to the City of Miami to bring my city's residents access to testing and information, and through our partnership with BioReference, we can help address this public health crisis."
"BioReference continues to prioritize expanding public access to COVID-19 testing across the nation," said Jon R. Cohen, M.D., Executive Chairman of BioReference Laboratories. "The importance of high-quality, reliable, scalable laboratory tests available is a critical part of the response in the effort to contain COVID-19."
https://www.opko.com/investors/news-events/press-releases/de…
Antwort auf Beitrag Nr.: 63.106.147 von Malecon am 23.03.20 19:46:52Schon verrückt wie die Shortis den Laden in den Boden stampfen. Irgendwann müssen sie kaufen und gestern hat der Kurs gehalten, keine panik verkaufe und starke Kauforder.
Durchsuchen
